Evidence map›Paper›PMID 32802314›Full record

ReviewF1000Research2020

The third model of Bax/Bak activation: a Bcl-2 family feud finally resolved?

Xu Luo, Katelyn L O'Neill, Kai Huang

Open access · goldAbstract readReview
In one paragraph

Review in F1000Research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed
4.1field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

40 citing papers in PubMed, 75 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Anti-Colorectal Cancer Activity ofInternational journal of molecular sciences · 2025
    Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Review
  17. The Impact of Panobinostat on Cell Death in Combination with S63845 in Multiple Myeloma Cells.Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion · 2023
    Article
  18. Review
  19. Apoptotic mitochondrial poration by a growing list of pore-forming BCL-2 family proteins.BioEssays : news and reviews in molecular, cellular and developmental biology · 2023
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Xu LuoEppley Institute for Research in Cancer and Allied Diseases, Fred & Pamela Buffett Cancer Center, University of Alaska Medical Center, Omaha, ME, 68198-7696, USA.
Katelyn L O'NeillEppley Institute for Research in Cancer and Allied Diseases, Fred & Pamela Buffett Cancer Center, University of Alaska Medical Center, Omaha, ME, 68198-7696, USA.
Kai HuangEppley Institute for Research in Cancer and Allied Diseases, Fred & Pamela Buffett Cancer Center, University of Alaska Medical Center, Omaha, ME, 68198-7696, USA.
Susan Thompson Buffett Foundation · USFred and Pamela Buffett Cancer Center

Funding

Research Pilot Project ProgramP30GM106397 · NIGMS · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI JOHNSON, KEITH R · 2013 to 2017
$4.9M
Mechanism of Bax/Bak Activation During ApoptosisR01GM118437 · NIGMS · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI LUO, XU · 2017 to 2020
$1.3M
Bax/Bak activation without direct activator BH3-only proteins in cancer cellsR03CA205496 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI LUO, XU · 2017 to 2018
$151k
NCI NIH HHS R03 CA205496NIGMS NIH HHS P30 GM106397NIGMS NIH HHS R01 GM118437
6 · The paper itself

Abstract

Bax and Bak, two functionally similar, pro-apoptotic proteins of the Bcl-2 family, are known as the gateway to apoptosis because of their requisite roles as effectors of mitochondrial outer membrane permeabilization (MOMP), a major step during mitochondria-dependent apoptosis. The mechanism of how cells turn Bax/Bak from inert molecules into fully active and lethal effectors had long been the focal point of a major debate centered around two competing, but not mutually exclusive, models: direct activation and indirect activation. After intensive research efforts for over two decades, it is now widely accepted that to initiate apoptosis, some of the BH3-only proteins, a subclass of the Bcl-2 family, directly engage Bax/Bak to trigger their conformational transformation and activation. However, a series of recent discoveries, using previously unavailable CRISPR-engineered cell systems, challenge the basic premise that undergirds the consensus and provide evidence for a novel and surprisingly simple model of Bax/Bak activation: the membrane (lipids)-mediated spontaneous model. This review will discuss the evidence, rationale, significance, and implications of this new model.

Indexed as

Apoptosisbcl-2-Associated X Proteinbcl-2 Homologous Antagonist-Killer ProteinHumansProto-Oncogene Proteins c-bcl-2bcl-2-Associated X Proteinbcl-2 Homologous Antagonist-Killer ProteinProto-Oncogene Proteins c-bcl-2ActivatorApoptosisauto-activationBadBakBaxBcl-2 familyBcl-xLBH3 mimeticsBH3-only proteinsBidBimde novo activationDirect activationIndirect activationMcl-1Membrane-mediated Spontaneous activationMitochondrial outer membraneretro-translocationSensitizer

Identifiers

PMID32802314
PMCPMC7411521
OpenAlexW3047744467

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.